Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>Resources>White Papers>This White Paper
  White Papers
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Scroll Up
Scroll Down

Dolomite and Clearbridge BioMedics develop revolutionary instrument for cancer detection
Bookmark and Share

Dolomite

Dolomite is delighted to announce its collaboration with Clearbridge BioMedics in the development of a novel instrument capable of detecting and isolating Circulating Tumour Cells (CTCs) from small quantities of whole, unprocessed blood.

The innovative ClearCell™ System can isolate, enumerate and most importantly retrieve wholly intact and viable CTCs from patient whole blood. Benefiting a broad range of application areas including molecule analysis, cancer diagnostics and cancer treatment decisions, this revolutionary instrument also paves the way for personalised cancer medication for patients.

Speaking of this success, Andrew Lovatt, the CEO of Dolomite, says, “We are excited to be working with an innovative company like Clearbridge BioMedics. The collaboration is an excellent example of how Dolomite is able to help start-up companies productize science. By combining the cutting edge scientific research of Clearbridge BioMedics and National University of Singapore with the proven track record in product development of Dolomite, both companies have leveraged their expertise to gain early traction in the

This white paper can be viewed by following the attached link.

Further Information

Related Content

Dolomite and GigaGen Collaborate to Develop Novel Droplet Merging Technology
Development of a novel Droplet Merger Chip for massively parallel single cell genetic analysis.
Friday, February 17, 2012
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!